Trials
8 active
25 in total · 9 in the EU
What this is
- How it works
- Blocks a kinase, an enzyme that passes "grow" or "activate" signals inside cells. Most are cancer drugs.-tinib: tyrosine kinase inhibitors WHO name stem
- Tested for
- Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia, Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
- Main trialPhase 1/2
- “People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster. Therefore, chemotherapy is less suitable to treat AML in people with the changed FLT3 gene. Gilteritinib, given with venetoclax and azacitidine, is a potential new treatment for people with AML with the changed FLT3 gene. They cannot have chemotherapy due to old age or other conditions. Before these combined 3 medicines are available as a treatment, the researchers need to understand how they are processed by and act upon…”In the company’s words, NCT05520567 on ClinicalTrials.gov
- Other names
- ASP2215 · Xospata
Other drugs for Acute Myeloid Leukemia (AML)
- Pivekimab SunirineAbbVie · Phase 2/3
- QTX-2101Quetzal Therapeutics · Phase 3
- ZiftomenibKura Oncology, Inc. · Phase 3
- QuizartinibDaiichi Sankyo · Phase 3
- MocravimodPriothera SAS · Phase 3
- ATOSDK Therapeutics, Inc. · Phase 3
Coming up2
- 31 Jul 2028Phase 1/2 trial completes · ClinicalTrials.gov
- 31 Dec 2029Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials25
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 31 Jul 2028 | A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | |
| Phase 1Recruiting | 31 Dec 2029 | A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) | |
| Phase 3Completed | 17 Sep 2018 | A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | |
| Phase 3Completed | 7 Jan 2023 | A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) | |
| Phase 3Completed | 10 Mar 2023 | A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy | |
| Phase 3Completed | 25 Dec 2023 | A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation | |
| Phase 2Completed | 25 May 2021 | A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission | |
| Phase 1/2Terminated | 28 Sep 2016 | A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI) | |
| Phase 1/2Completed | 4 Aug 2017 | Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | |
| Phase 1/2Completed | 28 Jul 2020 | Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial | |
| Phase 1/2Completed | 14 May 2021 | A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | |
| Phase 1/2Completed | 25 Aug 2021 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia. | |
| Phase 1/2Terminated | 11 Mar 2025 | A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | |
| Phase 1Completed | 5 Mar 2016 | A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215 | |
| Phase 1Completed | 27 Jun 2016 | Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia | |
| Phase 1Completed | 20 May 2017 | Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors | |
| Phase 1Completed | 2 Jul 2019 | A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects | |
| Phase 1Completed | 26 Jul 2021 | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | |
| Phase 1Completed | 18 Jul 2022 | A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal Function | |
| Phase 2Authorised | not given | HOVON 156 AML: A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy. | |
| Phase 1/2Authorised | not given | AGORA-1 /ALFA 2100 study : A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults with FLT3-ITD and/or FLT3-TKD relapse/refractory (R/R) AML | |
| Phase 2Authorised | not given | Sequential Gilteritinib in Combination with Venetoclax and Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutations Ineligible for Intensive Treatment (SEQUENCE) | |
| Phase 3Authorised | not given | IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA | |
| Phase 2Authorised | not given | A Phase II, Open-Label, multicentre, study investigating tolerability and efficacy of Gilteritinib in combination with fludarabine, cytarabine and idarubicin (FLAI) as induction therapy of newly diagnosed non-M3 FLT3-positive acute myeloid leukemia.GIMEMA AML2924 | |
| Phase 2Authorised | not given | An open-label, phase 2 study, evaluating the efficacy of treatment with Gilteritinib in measurable residual disease eradication in patients with FLT3-ITD mutated acute myeloid leukemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026